News

Resources are available to help patients through a chronic myeloid leukemia diagnosis and treatment.

The biologics license application for subcutaneous amivantamab is seeking approval for the treatment of EGFR-positive non-small cell lung cancer.

Patients with newly diagnosed, high-risk acute promyelocytic leukemia treated with a combination strategy of ATO plus ATRA and idarubicin experienced improvements in event-free survival.

As most adverse effects of chronic myeloid leukemia treatment are manageable, patients with the disease may be able to continue their normal lifestyle while receiving therapy.

The approval of this pembro-chemo combination for adults with primary advanced or recurrent endometrial carcinoma includes those with mismatch repair-proficient or -deficient disease.

Most patients with lower-risk myelofibrosis, over a 4-year period, experienced disease progression, as demonstrated by the prospective MOST study.

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.

A subgroup analysis of the TRANSCEND NHL 001 trial demonstrated that liso-cel may be more effective in earlier lines of treatment for patients with mantle cell lymphoma.

The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.

The FDA approved durvalumab plus carboplatin and paclitaxel, followed by single-agent durvalumab for primary advanced or recurrent dMMR endometrial cancer.

Patients with relapsed/refractory multiple myeloma who also had a lower tumor burden were more likely to derive deeper responses to idecabtagene vicleucel.

Findings from a retrospective study may shed light on the prognostic value of PD-L1 expression in metastatic papillary renal cell carcinoma.

Patient-provider conversations are vital to promote the best care for chronic myeloid leukemia, a patient advocate said.

The FDA granted accelerated approval to repotrectinib to treat adult and pediatric patients with NTRK gene fusion-positive solid tumors.

Compared with fulvestrant alone, abemaciclib plus fulvestrant improved progression-free survival in select patients with hormone receptor–positive/HER2-negative advanced breast cancer.

This traditional approval updates the accelerated approval that selpercatinib received in 2020 for this indication in patients 12 years and older.

Oncology nurses can help optimize quality of life in patients by addressing interrelated symptom clusters.

Patients with advanced renal cell carcinoma with previous exposure to lenvatinib derived modest benefit with tyrosine kinase inhibitors.

The priority review granted by the FDA to the supplemental new drug application for osimertinib is seeking approval for its treatment of stage III non-small cell lung cancer with EGFR mutations.

Adding darolutamide to androgen deprivation therapy and docetaxel delayed the progression from metastatic hormone-sensitive prostate cancer to metastatic castration-resistant disease.

Patients with HER2-positive early breast cancer derived similar outcomes whether they received subcutaneous or intravenous pertuzumab and trastuzumab plus chemo.

Patients treated with enfortumab vedotin before sacituzumab govitecan had low objective response rates and median PFS, which may raise questions about this sequencing approach.

Rates of MRD negativity increased with daratumumab plus VRd in newly diagnosed, transplant-eligible multiple myeloma.

Treatment with fuzuloparib, either with or without apatinib, provided superior progression-free survival benefit compared with chemotherapy in HER2– metastatic breast cancer with germline BRCA1/2 mutations.

Oral azacitidine had a similar safety profile across the 200-mg and 300-mg groups in lower- to intermediate-risk MDS.

Patients with biochemically recurrent nonmetastatic hormone-sensitive prostate cancer who are responding well to an enzalutamide regimen may be able to stop treatment with an impact to their quality of life.

The FDA granted an approval to imetelstat for certain patients with low- to intermediate-1-risk MDS who have transfusion-dependent anemia.

Patients with recurrent ovarian cancer did not derive a benefit from adding atezolizumab to chemotherapy and bevacizumab.

Tucidinostat plus R-CHOP was safe and effective for previously untreated diffuse large B-cell lymphoma expressing MYC and BCL-2.

Oncology nurses can aid in the identification and management of oral adverse effects from cancer therapies.